table2_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

table1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

datasheet1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.pdf by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

table1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

datasheet1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.pdf by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

table3_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

table2_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

datasheet1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.pdf by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

table1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.xlsx by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

datasheet1_miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.pdf by María Sol Ruiz (9966293)

“…<p>Chronic myeloid leukemia (CML) is a myeloid stem cell neoplasm characterized by an expansion of myeloid progenitor cells and the presence of BCR-ABL1 oncoprotein. …”

Figure 6 from Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes by Laura Kuett (20493991)

“…Circles display significantly enriched (red) or decreased (blue; FDR < 0.05; multiple testing correction with the Benjamin–Hochberg method) results, with size indicating the log-transformed fold change.  …”

Table_1_The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Ra... by Philip C. Spinella (5181788)

“…The fold decrease in plasma IL-6 was significantly less in the 4 g TXA group [1.36 (0.87–2.42)] compared to the placebo group [0.46 (0.19–1.69)] at 72 h post-TXA (p = 0.028). …”

Supplementary Tables S1 and S2 by Thomas Clanton (9323303)

“…In the second hour of exposure, though G-CSF, IL-6, KC(CXCL1) and MCP-1(CCL2) were elevated nearly 5-10-fold compared to the first hour, only MCP-1 decreased secretion in LyzMyd88^-/- muscles. …”

Table_1_Synthetic antimicrobial peptides Bac-5, BMAP-28, and Syn-1 can inhibit bovine respiratory disease pathogens in vitro.DOCX by Santiago Cornejo (19366597)

“…When used alone, the MIC of BMAP-28 and Bac-5 was 64 and 128 μg/mL respectively, but when applied together, their MIC ranged from 0.25–16 for BMAP-28 and 8–64 μg/mL for Bac-5, resulting in a decrease in concentration of up to 256 and 16-fold, respectively. …”

DataSheet_1_Single-Cell RNA Sequencing Reveals the Immunological Profiles of Renal Allograft Rejection in Mice.pdf by Qixia Shen (11170275)

“…Both B cells and neutrophils decreased by about 3 folds. On the contrary, the proportion of macrophages and dendritic cells (DCs) increased significantly, especially by about a 4.5-fold increase in Ly6c^loMrc1⁺ macrophages and 2.6 folds increase in Ly6c^loEar2⁺ macrophages. …”

Table_1_Dysregulation of Principal Circulating miRNAs in Non-human Primates Following Ischemic Stroke.XLSX by Jian Chen (15340)

“…After cerebral ischemia, Rfam sequence category revealed increased ribosomic RNA (rRNA) and decreased transfer RNAs (tRNAs) in plasma. Of the 2049 miRNAs detected after cerebral ischemia, 36 were upregulated, and 76 were downregulated (fold change ≥2.0, P < 0.05). …”

DataSheet_1_Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary disease.docx by Charlotte de Fays (17177770)

“…Transcriptomics of each core assessed fold changes in innate and adaptive cells and pathway enrichment score between control and COPD cores. …”

DataSheet_1_IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.pdf by Irina A. Elcheva (16531356)

“…Increased immunogenicity, associated with Igf2bp1 inhibition, “inflames” mouse melanoma tumors microenvironment in SM1/C57BL/6 and SW1/C3H mouse models measured by a two-fold increase of NK cells and tumor-associated myeloid cells. …”

DataSheet_1_IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.pdf by Irina A. Elcheva (16531356)

“…Increased immunogenicity, associated with Igf2bp1 inhibition, “inflames” mouse melanoma tumors microenvironment in SM1/C57BL/6 and SW1/C3H mouse models measured by a two-fold increase of NK cells and tumor-associated myeloid cells. …”

DataSheet1_Mesenchymal stem cells induce dynamic immunomodulation of airway and systemic immune cells in vivo but do not improve survival for mice with H1N1 virus-induced acute lun... by Yuan Tan (819132)

“…While MSC treatment accentuated changes in these populations, naïve B, antibody-secreting B cells, and T cells were decreased in MSC-treated animals at day 3. Compared to sham animals, IAV infection induced a significant 5.5-fold increase in BAL total cell counts, including CD4⁺ and CD8⁺ T cells, CD19⁺ B cells, CD11b + Ly6G + neutrophils, and CD11b + Ly6C + monocytes. …”